SCHEMBL25413622

SCHEMBL25413622

O=C(O)N1CC2(CCC(F)(c3ccccc3)CC2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.42
OPRM1 P35372 4/20 0.39
OPRL1 P41146 3/20 0.39
CYP2C19 P33261 4/20 0.39
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP3A4 P08684 5/20 0.38
HIF1A Q16665 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
AKR1C1 Q04828 1/20 0.37
USP2 O75604 2/20 0.36
HSD17B10 Q99714 1/20 0.36
ALOX15 P16050 2/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 3/20 0.35
CYP1A2 P05177 3/20 0.35
CYP2C9 P11712 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25412584 0.81 OPRL1 (0.46) HSD11B1OPRM1OPRL1CYP2C19MAPK1
SCHEMBL12469550 0.81 HSD11B1 (0.46) HSD11B1OPRM1ALDH1A1MEN1KMT2A
SCHEMBL26739282 0.78 MGLL (0.40) OPRM1OPRL1USP2CYP2C9
SCHEMBL26631103 0.78 MGLL (0.40) OPRM1OPRL1USP2CYP2C9
SCHEMBL19992871 0.75 MAOB (0.48) OPRM1OPRL1MEN1KMT2ACYP2C9
SCHEMBL30557323 0.75
SCHEMBL23034990 0.72 SCD5 (0.56) HSD11B1OPRM1OPRL1CYP2C19ALDH1A1
SCHEMBL25410405 0.71 OPRL1 (0.48) OPRM1OPRL1CYP2C19CYP3A4TSHR
SCHEMBL1669519 0.71 GRIN2B (0.44) HSD11B1OPRM1OPRL1ALDH1A1MEN1
SCHEMBL18711663 0.70 NOTUM (0.46) OPRM1CYP2C19MAPK1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 US disclosed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP HSD11B1 97/4885OPRM1 275/4885OPRL1 28/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP HSD11B1 91/4885OPRM1 289/4885OPRL1 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.